Chronic Kidney Disease Improvement in Research and Treatment Act of 2014

Health care reimbursement policy. H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Healthcare reform In-home dialysis H.R. 4814 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014 H.R.83 - Consolidated and Further Continuing Appropriations Act

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and Regulation Relating to Caring for Patients with Kidney Disease. HR 4814, The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and Regulation Relating to Caring for Patients with Kidney Disease. HR 4814, The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and Regulation Relating to Caring for Patients with Kidney Disease. HR 4814, The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare &Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule; ESRD quality programs; ESRD Dialysis Facility Compare and Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies;Proposed Rule [CMS-1614-P]; Exchange function for individuals with ESRD; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); Medicare and state health care programs: fraud and abuse; revisions to Safe Harbors under the Anti-Kickback Statute; Civil Monetary Penalty Rules Regarding Beneficiary Inducements and Gainsharing: Proposed Rule, 79 Fed. Reg. 59717 (Oct.3, 2014). Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).

Client expense: $300,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare &Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule; ESRD quality programs; ESRD Dialysis Facility Compare and Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies;Proposed Rule [CMS-1614-P]; Exchange function for individuals with ESRD; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); Medicare and state health care programs: fraud and abuse; revisions to Safe Harbors under the Anti-Kickback Statute; Civil Monetary Penalty Rules Regarding Beneficiary Inducements and Gainsharing: Proposed Rule, 79 Fed. Reg. 59717 (Oct.3, 2014). Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).

Client expense: $300,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Legislation to cut Medicare Part B Drug Reimbursement, Medicare Part B DME Competitive Bidding Program. Raise awareness with legislators about the barriers to and the importance of protecting access for home dialysis. Pull through on Medicare demonstration to provide nursing services and supplies associated with home infusion of IVIG for patients with PIDD. HR 3613: Part D Beneficiary Appeals Fairness Act - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. Medicare Part B Drug Reimbursement. H.R. 8 American Taxpayer Relief Act of 2012 -- working to mitigate the impact to kidney patients of the payment reductions required by the Act. HR 3306: Telehealth Enhancement Act of 2013. HR4814-The Chronic Kidney Disease Improvement in research and Treatment Act of 2014.

Client expense: $640,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocate for the development of an X-Prize in kidney treatment and innovation. Work to develop analytical tools for Congress to better understand the need for innovation in kidney care to improve treatment outcomes and lower costs. Advocate support for HR 4814 and for telehealth expansion.

Client expense: $12,387 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25). Final Regulations issued by CMS regading Medicare payments for services for people living with ESRD. Proposal at the Center for Medicare and Medicaid Innovation to develop a coordinated kidney care pilot program that would integrate care for Medicare beneficiaries with ESRD. CMS call letter for Medicare Advantage plans with a focus on rate setting and risk adjustment issues. H.R. 4814: The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014 (All provisions) CMS regulations related to the treatment of Medicare Part C and D. CMS regulations pretaining to reimbursement rates for ESRD-related services. S. 2501: Hospital Readmissions Program Accuracy and Accountability Act (All provisions) H.R. 5481: The Flexibility in Health IT Reporting Act of 2014 "Flex-IT Act" (All provisions)

Client expense: $1,000,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25). Final Regulations issued by CMS regading Medicare payments for services for people living with ESRD. Proposal at the Center for Medicare and Medicaid Innovation to develop a coordinated kidney care pilot program that would integrate care for Medicare beneficiaries with ESRD. CMS call letter for Medicare Advantage plans with a focus on rate setting and risk adjustment issues. H.R. 4814: The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014 (All provisions) CMS regulations related to the treatment of Medicare Part C and D. CMS regulations pretaining to reimbursement rates for ESRD-related services. S. 2501: Hospital Readmissions Program Accuracy and Accountability Act (All provisions) H.R. 5380: Medicare Telehealth Parity Act of 2014 (All provisions)

Client expense: $1,000,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; ESRD Five Star Rating

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; ESRD Five Star Rating

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; ESRD Five Star Rating

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; ESRD Five Star Rating

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Implementation of the Patient Protection and Affordable Care Act Initiatives to increase and facilitate organ transplantation, including H.R. 5263, "Living Donor Protection Act" H.R. 4814, "Chronic Kidney Disease Improvement in Research and Training Act of 2014" Comments to FDA regarding patient input on medical product discussion and patient-focused drug development Patient access to drug therapies

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 4994 - The IMPACT ACT - focused on studies to assess the treatment of Socioeconomic Status in health care quality measurement. H.R. 4814 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014 Promoting amendments to the Health Reform law to apply Medicare Secondary Payer provisions for ESRD patients in the Exchanges. H.R. 647 - Achieving a Better Life Experience Act - provisions that would offset this legislation, which impact people living with ESRD. CMS regulations related to the treatment of part C and D. CMS regulations pertaining to reimbursement rates for ESRD-related services. Policies related to risk adjustment and their impacts on serving chronically ill patients.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4994 - The IMPACT ACT - focused on studies to assess the treatment of Socioeconomic Status in health care quality measurement. H.R. 4814 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014 Promoting amendments to the Health Reform law to apply Medicare Secondary Payer provisions for ESRD patients in the Exchanges. H.R. 647 - Achieving a Better Life Experience Act - provisions that would offset this legislation, which impact people living with ESRD. CMS regulations related to the treatment of part C and D. CMS regulations pertaining to reimbursement rates for ESRD-related services. Policies related to risk adjustment and their impacts on serving chronically ill patients.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare ERSD proposed rule (CMS-1614-P); H.R. 4814-Chronic Kidney Disease Improvement in Research and Treatment Act; issues related to advanced practice nursing and home health.

Client expense: Not reported · Firm income: $20,000

S. 323/H.R. 1428 to extend immunosuppressive drug coverage beyond the current three year cap; Encourage Congress to open Medicare Advantage to dialysis patients; H.R. 4814 to improve kidney disease research and treatment; and Refinement of Star Ratings for Dialysis Facility Compare.

Client expense: $10,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25). HR 4814 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014. CMS regulations related to the treatment of Medicare Part C and D.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated in support of HR 4814, the Chronic Kidney Disease Treatment and Innovation Act of 2014

Client expense: $15,007 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule; ESRD quality programs; ESRD Dialysis Facility Compare and Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]. Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).

Client expense: $250,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule; ESRD quality programs; ESRD Dialysis Facility Compare and Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]. Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).

Client expense: $250,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Healthcare reform In-home dialysis H.R. 4814 - The Chronic Kidney Disease Improvement in Research and Treatment Act os 2014

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and Regulation Relating to Caring for Patients with Kidney Disease. HR 4814, The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and Regulation Relating to Caring for Patients with Kidney Disease. HR 4814, The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and Regulation Relating to Caring for Patients with Kidney Disease. HR 4814, The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to cut Medicare Part B Drug Reimbursement, Medicare Part B DME Competitive Bidding Program. Raise awareness with legislators about the barriers to and the importance of protecting access for home dialysis. Pull through on Medicare demonstration to provide nursing services and supplies associated with home infusion of IVIG for patients with PIDD.HR 3613: Part D Beneficiary Appeals Fairness Act - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act, with respect to a prescription drug plan (PDP) that provides for any tiered cost-sharing within a formulary (including a structure that provides for different co-payment or coinsurance amounts for drugs in different tiers included within the formulary), to authorize a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure. Medicare Part B Drug Reimbursement. H.R. 8 American Taxpayer Relief Act of 2012 -- working to mitigate the impact to kidney patients of the payment reductions required by the Act. HR 3306: Telehealth Enhancement Act of 2013. HR4814-The Chronic Kidney Disease Improvement in research and Treatment Act of 2014.

Client expense: $550,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

End Stage Renal Disease and issues related to dialysis Medicare Part B drug reimbursement issues (Average Sales Price) H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act (End Stage Renal Disease) 2015 Labor/HHS Senate Appropriations draft committee report (340B drug pricing program)

Client expense: Not reported · Firm income: $2,080,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

Medicare reimbursement policy. H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25). Final Regulations issued by CMS regading Medicare payments for services for people living with ESRD. Proposal at the Center for Medicare and Medicaid Innovation to develop a coordinated kidney care pilot program that would integrate care for Medicare beneficiaries with ESRD. CMS call letter for Medicare Advantage plans with a focus on rate setting and risk adjustment issues. HR 4814 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014. CMS regulations related to the treatment of Medicare Part C and D. CMS regulations pretaining to reimbursement rates for ESRD-related services. S. 2501 Hospital Readmissions Program Accuracy and Accountability Act.

Client expense: $840,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25). Final Regulations issued by CMS regading Medicare payments for services for people living with ESRD. Proposal at the Center for Medicare and Medicaid Innovation to develop a coordinated kidney care pilot program that would integrate care for Medicare beneficiaries with ESRD. CMS call letter for Medicare Advantage plans with a focus on rate setting and risk adjustment issues. HR 4814 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014. CMS regulations related to the treatment of Medicare Part C and D. CMS regulations pretaining to reimbursement rates for ESRD-related services. S. 2501 Hospital Readmissions Program Accuracy and Accountability Act.

Client expense: $840,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)

Implementation of P.L. 111-148 Patient Protection and Affordable Care Act; ESRD PPS and QIP rules; physician fee schedule rule; ESRD quality programs; ESRD Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Implementation of P.L. 111-148 Patient Protection and Affordable Care Act; ESRD PPS and QIP rules; physician fee schedule rule; ESRD quality programs; ESRD Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Budget Control Act of 2011 (P.L. 112-25); Patient Protection and Affordable Care Act (P.L. 111-148); Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the end-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Budget Control Act of 2011 (P.L. 112-25); Patient Protection and Affordable Care Act (P.L. 111-148); Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the end-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Budget Control Act of 2011 (P.L. 112-25); Patient Protection and Affordable Care Act (P.L. 111-148); Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the end-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Budget Control Act of 2011 (P.L. 112-25); Patient Protection and Affordable Care Act (P.L. 111-148); Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); American Taxpayer Relief Act of 2012 (P.L. 112-240); Comprehensive ESRD Care Initiative; CMS-1614-P: CY 2015 Changes to the end-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, and Changes to the Change in Ownership Policy for Durable Medical Equipment, Prosthetics, Orthotics and Supplies; H.R. 4302, the Protecting Access to Medicare Act of 2014; H.R. 4814, Chronic Kidney Disease Improvement in Research and Treatment Act of 2014

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 323 and H.R. 1428, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" H.R. 4188, "Establishing Beneficiary Equity in the Hospital Readmission Program Act" H.R. 4814, "Chronic Kidney Disease Improvement in Research and Training Act of 2014" Comments on the Medicare prospective payment system for dialysis Comments on Medicare coverage of dialysis for hospice patients Comments regarding Medicare Advantage and Part D payment issues for kidney patients

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare ERSD proposed rule (CMS-1614-P); H.R. 4814-Chronic Kidney Disease Improvement in Research and Treatment Act; and H.R. 5263, the Living Donor Protection House Act.

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES

H.R. 4994 - The IMPACT ACT. Focused on provisions requiring the study of socioeconomic status as a measurement for quality initiatives in the Medicare and Medicaid programs. HR 4814 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014. Working in support of a partnership with the Administration ( specifically with CMMI) on a Coordinated Kidney Care pilot program that would integrate care for Medicare beneficiaries living with End State Renal Disease. Promoting amendments to the health reform law to apply Medicare Secondary Payer provisions for ESRD patients in the Exchange. Promoting amendments to the Medicare law to allow people with ESRD to opt for coverage through the Medicare Advantage program. CMS regulations related to the treatment of Medicare Part C CMS regulations related to ESRD-related services. Issue related to rate setting and risk adjustment for Medicare Advantage plans

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4994 - The IMPACT ACT. Focused on provisions requiring the study of socioeconomic status as a measurement for quality initiatives in the Medicare and Medicaid programs. HR 4814 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014. Working in support of a partnership with the Administration ( specifically with CMMI) on a Coordinated Kidney Care pilot program that would integrate care for Medicare beneficiaries living with End State Renal Disease. Promoting amendments to the health reform law to apply Medicare Secondary Payer provisions for ESRD patients in the Exchange. Promoting amendments to the Medicare law to allow people with ESRD to opt for coverage through the Medicare Advantage program. CMS regulations related to the treatment of Medicare Part C CMS regulations related to ESRD-related services. Issue related to rate setting and risk adjustment for Medicare Advantage plans

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to cut Medicare Part B Drug Reimbursement, Medicare Part B DME Competitive Bidding Program. Raise awareness with legislators about the barriers to and the importance of protecting access for home dialysis. Pull through on Medicare demonstration to provide nursing services and supplies associated with home infusion of IVIG for patients with PIDD.H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014. To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes.

Client expense: $900,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE